Gilead Sciences Inc. (NASDAQ:GILD) shares traded -2.18% lower at $75.67 on Wall Street last session.
In accordance with the data, 29 analysts cover Gilead Sciences Inc. (NASDAQ:GILD). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $116.00 and a low of $71.00, we find $90.50. Given the previous closing price of $77.36, this indicates a potential upside of 16.99 percent. GILD stock price is now -2.04% away from the 50-day moving average and -6.46% away from the 200-day moving average. The market capitalization of the company currently stands at $96.39B.
It has been rated a hold by 14 analysts and a buy by 13. Brokers who have rated the stock have averaged $90.86 as their price target over the next twelve months.
With the price target enhanced from $88 to $95, BofA Securities Upgraded its rating from Neutral to Buy for Gilead Sciences Inc. (NASDAQ: GILD).
In other news, Parsey Merdad, Chief Medical Officer sold 1,501 shares of the company’s stock on Sep 12. The stock was sold for $115,562 at an average price of $76.99. Upon completion of the transaction, the Chief Medical Officer now directly owns 70,130 shares in the company, valued at $5.31 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 20, Chief Financial Officer Dickinson Andrew D sold 5,000 shares of the business’s stock. A total of $400,000 was realized by selling the stock at an average price of $80.00. This leaves the insider owning 107,587 shares of the company worth $8.14 million. Insiders disposed of 229,067 shares of company stock worth roughly $17.33 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GILD stock. A new stake in Gilead Sciences Inc. shares was purchased by UNISUPER MANAGEMENT PTY LTD during the first quarter worth $23,774,000. TWINBEECH CAPITAL LP invested $21,231,000 in shares of GILD during the first quarter. In the first quarter, EXODUSPOINT CAPITAL MANAGEMENT, LP acquired a new stake in Gilead Sciences Inc. valued at approximately $21,133,000. GENUS CAPITAL MANAGEMENT INC. acquired a new stake in GILD for approximately $11,478,000. SIMPLEX TRADING, LLC purchased a new stake in GILD valued at around $9,256,000 in the second quarter.
Gilead Sciences Inc. (NASDAQ: GILD) opened at $77.21 on Friday. During the past 12 months, Gilead Sciences Inc. has had a low of $61.44 and a high of $89.74. As of last week, the company has a debt-to-equity ratio of 1.19, a current ratio of 1.00, and a quick ratio of 0.90. According to the stock market information, the enterprise value for the company is $112.86B, which is based on a 17.41 price-to-earnings ratio, a 3.93 price-to-earnings-growth ratio, and a beta of 0.39. The fifty day moving average price for GILD is $77.24 and a two-hundred day moving average price translates $80.85 for the stock.
The latest earnings results from Gilead Sciences Inc. (NASDAQ: GILD) was released for Jun, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.34, missing analysts’ expectations of $1.64 by -0.3. This compares to $0.90 EPS in the same period last year. The net profit margin was 20.00% and return on equity was 26.00% for GILD. The company reported revenue of $6.6 billion for the quarter, compared to $6.26 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.42 percent. For the current quarter, analysts expect GILD to generate $6.81B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 09/28/2023. Investors who held shares on 09/15/2023 were paid a $0.75 dividend. On an annualized basis, this represents a $3.00 dividend and a 3.96% percent yield. There was an ex-dividend date of 09/14/2023 for this dividend. In terms of dividend payout ratio, GILD is presently at 67.60%.
Gilead Sciences Inc.(GILD) Company Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc. and Tentarix Biotherapeutics Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
